November 28, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari-september 2023 Read more
November 28, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January-September 2023 Read more
November 21, 2023 Regulatory InDex Pharmaceuticals discontinues cobitolimod phase III program Read more
November 21, 2023 Regulatory InDex Pharmaceuticals avbryter fas III-programmet med cobitolimod Read more
November 21, 2023 Regulatory InDex Pharmaceuticals avbryter fas III-programmet med cobitolimod Read more
October 30, 2023 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2024 Annual General Meeting Read more
October 30, 2023 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2024 Read more
October 20, 2023 Non Regulatory InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea Read more
October 20, 2023 Non Regulatory InDex Pharmaceuticals har beviljats ett nytt patent för cobitolimod i Sydkorea Read more
October 11, 2023 Non Regulatory InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE Read more
October 11, 2023 Non Regulatory InDex Pharmaceuticals meddelar att alla patienter som krävs för att nå milstolpen för dosvalet av cobitolimod har slutfört Induktionsstudie 1 av fas III-programmet CONCLUDE Read more
October 5, 2023 Non Regulatory InDex Pharmaceuticals deltar vid United European Gastroenterology Week 2023 Read more
August 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2023 Read more
August 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2023 Read more
August 22, 2023 Non Regulatory ”Positive results from PK study with cobitolimod” selected as one of the best abstracts for poster presentation at UEGW Read more
August 22, 2023 Non Regulatory ”Positiva resultat från PK-studie med cobitolimod” utsedd till en av de bästa abstrakten för posterpresentation vid UEGW Read more
August 2, 2023 Regulatory InDex Pharmaceuticals has been granted a new patent in Europe for the commercial formulation of cobitolimod Read more
August 2, 2023 Regulatory InDex Pharmaceuticals har beviljats ett nytt patent i Europa för den kommersiella formuleringen av cobitolimod Read more
May 31, 2023 Non Regulatory InDex Pharmaceuticals investeraruppdatering 1 juni kl. 15:00 CET Read more
May 31, 2023 Non Regulatory InDex Pharmaceuticals investeraruppdatering 1 juni kl. 15:00 CET Read more
May 31, 2023 Regulatory InDex Pharmaceuticals announces license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan Read more
May 31, 2023 Regulatory InDex Pharmaceuticals och Viatris Japan ingår licensavtal för att utveckla och kommersialisera cobitolimod i Japan Read more